Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2021-05-11 Board/Management Inform…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019''.
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on May 11, 2021. It includes multiple items such as approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2021, declaration of audit opinion, recommendation of final dividend, re-appointment of auditors, issuance and allotment of shares under an employee stock option plan, re-appointment and resignation of directors, and reconstitution of board committees. The document references regulatory compliance under SEBI regulations and includes annexures with detailed disclosures. The content is primarily an announcement of decisions made by the Board rather than the full financial report itself. The document length is 13,641 characters, which is substantial but the nature of the content is consistent with a Board/Management Information announcement, especially given the inclusion of management changes and share allotment details. Therefore, the most appropriate classification is Board/Management Information (MANG).
2021-05-11 English
Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021, subject to approval of the shareholders in ....
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on May 11, 2021. It includes multiple items such as approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2021, declaration of audit opinion, recommendation of final dividend, re-appointment of internal auditor, issuance and allotment of shares under an ESOP plan, re-appointment and resignation of directors, appointment of a new Managing Director, and reconstitution of board committees. The document references regulatory compliance with SEBI Listing Obligations and Disclosure Requirements and includes annexures with further details. The content is primarily an announcement of decisions made by the board rather than the full financial report itself. The document length is about 5,341 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Regulatory Filings (RNS), as it is a general regulatory announcement covering multiple corporate governance and financial disclosures but does not contain the full financial statements or detailed report itself.
2021-05-11 English
1. Resignation of Mr. S N Kamath from the position of Managing Director as well as membership from all committees of board of the Company with immediate effect i.e. May 11, 2021; ....
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on May 11, 2021. It includes multiple items such as approval of audited financial results for the quarter and year ended March 31, 2021, declaration of audit opinion, recommendation of final dividend, re-appointment of auditors, issuance and allotment of shares under an ESOP plan, re-appointment and resignation of directors, appointment of a new Managing Director, and reconstitution of board committees. The document contains specific regulatory references to SEBI regulations and includes annexures with profiles of directors. The content is primarily about board decisions and management changes rather than the full financial report itself. It also includes share capital changes and director appointments/resignations. Given the focus on board decisions, management appointments, and share capital changes, the document fits best under Board/Management Information (MANG). It is not a full annual report or audit report, nor is it a simple announcement of a report publication. The length and detail confirm it is not a brief announcement but a substantive board meeting outcome disclosure.
2021-05-11 English
Financial Result Updates
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on May 11, 2021. It includes multiple items such as approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2021, declaration of audit opinion, recommendation of final dividend, re-appointment of auditors, issuance and allotment of shares under an employee stock option plan, re-appointment and resignation of directors, and reconstitution of board committees. The document references the audited financial results and audit reports as annexures but does not itself contain the full financial statements or detailed financial analysis. It is primarily an announcement of the board meeting outcomes including financial results approval and management changes. Given the comprehensive nature of the board meeting outcomes including management changes and financial results approval, but without the full financial report text, this fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Annual Report (10-K) or Audit Report (AR).
2021-05-11 English
1. Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report with declaration of unmodified opinion ....
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Ltd. regarding the outcome of a Board Meeting held on May 11, 2021. It includes multiple items such as approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2021, declaration of unmodified audit opinion, recommendation of final dividend, re-appointment of auditors, issuance and allotment of shares under an employee stock option plan, re-appointment and resignation of directors, and reconstitution of board committees. The document references Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which govern disclosures related to financial results and board decisions. The content is comprehensive and includes substantive financial data (audited results) and corporate governance changes (appointments and resignations of directors). This combination of financial results and management/board changes is typical of a Board/Management Information filing. It is not merely an announcement of a report publication, nor is it a full annual report or audit report standalone. It also includes capital changes (share allotment) but the primary focus is on board meeting outcomes and financial results approval. Therefore, the most appropriate classification is Board/Management Information (MANG).
2021-05-11 English
Pursuant to Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the newspaper ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) regarding a newspaper advertisement of a notice of a Board Meeting. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and mentions the Board Meeting scheduled to approve audited standalone and consolidated financial statements and results for the quarter and year ended March 31, 2021. The document is essentially an announcement of the notice of the Board Meeting and the publication of the financial results in newspapers. It does not contain the financial statements or detailed financial data itself, nor is it a transcript or report. The document is about the advertisement of the notice of the Board Meeting and the publication of results, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance document. The document length is 15,000 characters, but the content is an announcement rather than the report itself, so it is not classified as an Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-05-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.